VTAAC provides a forum for collaboration, engagement and sharing of resources for individuals and organizations concerned about cancer in Vermont.

The University of Vermont Cancer Center will present the 22nd Annual Conference as a day of education for patients, survivors, health care providers, family members, and all others interested in women's health.

New Pilot Project funding available for July 1, 2020 start date.

Complementary Contributions of Tobacco Control & Regulatory Science Research to Protecting the Public Health

Save the Date for the 2019 NIA Director's Regional Meeting

Click here for a curated and updated list of summaries of CTR-relevant funding opportunities.

After careful peer review of 29 applications submitted in April 2018, we are pleased to announce the five Round 2 Northern New England Clinical & Translational Research Network pilot project award winners.

RNAscope is an RNA in situ detection platform. The RNAscope® Assays are based on the proprietary RNAscope® Technology, enabling RNA target expression analysis within intact cells and tissues with high sensitivity and specificity. The innovative RNAscope® Assay, with in situ hybridization technology to detect mRNA and ncRNA targets of >300bp, was launched in 2011 and marks the foundation of our product portfolio. The proprietary probe design requires an average of 20 Z pairs per target, however a minimum hybridization of 6 Z pairs can be used to obtain a signal. With over 1,400 publications in peer-reviewed journals, across multiple disciplines, the RNAscope® Assay represents a revolutionary advance in in situ target RNA detection. The seminar highlighted the basis of RNAscope technology and labeling protocols, including troubleshooting tips and examples of labeling with both chromogenic and fluorescent dyes.

Click on the title for a link to access article.

An innovative initiative that will use a public health approach to inform opioid prescribing policies will be launched in northern New England thanks to a new $339,000 grant to the Northern New England Clinical and Translational Research (NNE-CTR) Network from the National Institutes of Health.

In its first year of accepting grant requests, the Pilot Project Program of the Northern New England Clinical & Translational Research Network received nearly 60 Letters of Intent (LOIs) for potential study funding.  A handful in each of the first two rounds highlighted cancer-related aims. Due to limited funding, only the most fully-developed programs were approved, while others were encouraged to further develop and resubmit in future rounds.